Understanding type 1 diabetes with AI and glucose data
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study uses artificial intelligence to analyze glucose monitor data from people with type 1 diabetes. The goal is to find patterns that could improve care and treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have type 1 diabetes.
- You use a continuous glucose monitor (CGM) and have been using it for at least the last 6 months of 2024.
- You are seen regularly at the Endocrinology and Nutrition Department of Hospital de la Santa Creu i Sant Pau.
- You are willing to sign a consent form to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether an artificial intelligence (AI) system can help manage insulin pump therapy remotely for people with type 1 diabetes. The goal is to improve blood sugar control and make diabetes management easier.
This trial tests a new continuous glucose monitor (CGM) designed to help manage blood sugar levels. You will wear the device for 15 days and attend three clinic visits to see how well it works.
This study uses a wearable sensor (like a smartwatch) to track your body's signals when blood sugar drops low. The goal is to understand low blood sugar patterns better, which may help improve prevention and treatment.
This study tests an artificial intelligence tool that uses ECG (a heart tracing) to spot likely blood sugar changes in people with type 1 diabetes. It may help improve earlier detection of “glycaemic events” without invasive testing.
This study looks at how people with type 1 diabetes are treated and how their metabolism is doing. It will help doctors understand the condition better and improve care.
This study uses artificial intelligence to better understand type 2 diabetes. It is open to adults with or without type 2 diabetes, and aims to improve care for everyone.
Hear when a new Type 1 Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.